Murray W. Enns
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Murray W. Enns has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
- Natalie Mota
Departments of Clinical Health Psychology and Psychiatry, University of Manitoba, Winnipeg, Canada
14 shared publications - Tracie O. Afifi
University of Manitoba, Winnipeg, Canada
13 shared publications - Shay-Lee Bolton
Affiliations Department of Psychiatry, University of Manitoba, Winnipeg, Manitoba, Canada, Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada, Department of Psychology, University of Manitoba, Winnipeg, Manitoba, Canada
12 shared publications Jitender Sareen
Department of Psychiatry, University of Manitoba, Winnipeg, Manitoba, Canada
10 shared publications- Jitender Sareen
Department of Psychiatry University of Manitoba Winnipeg Manitoba Canada
10 shared publications Charles N. Bernstein
Department of Internal Medicine, Max Rady College of Medicine, University of Manitoba, Canada
4 shared publications
Latest Publications
- 1 November 2026
- Published by University of Toronto Press Inc. (UTPress) in Journal of Military, Veteran and Family Health
- Vol. 12 (5) , 131-142
Predictors of remission and progression of suicidal ideation in the Canadian Armed Forces: A 16-year nationally representative longitudinal study
Introduction: Given that suicidal ideation (SI) is a key risk factor for future suicidal behaviour, socio-economic and psychosocial factors that influence the critical transition period between suicidal ideation, plans, and attempts in the military should be examined. This study assessed correlates of remission and progression (i.e., worsening) of suicidality in a 16-year prospective, nationally representative sample of Canadian Armed Forces members and Veterans. Methods: The 2018 Canadian Armed Forces Members and Veterans Mental Health Follow-up Survey (n = 2,941) is a follow-up of respondents of the 2002 Canadian Community Health Survey – Canadian Forces Supplement. The reporting of SI in 2002 was used to create three groups in 2018: 1) remission (no SI, suicidal plans [SP], or suicidal attempts [SA] “since last interview”), 2) persistence (SI “since last interview”, but not SP or SA), and 3) progression (SP and/or SA “since last interview”). Results: Relative to SI persistence, all six mental disorders examined in 2018 were negatively associated with SI remission (odds ratio [OR] range 0.29-0.42) or positively associated with SI progression (OR range 3.69-5.92). Coping styles and deployment had statistically significant associations with remission, while military environmental command, military rank, physical health conditions, and traumatic exposure were significantly associated with progression. Discussion: Potential interventions could focus on developing psychological strategies to enhance resilience to trauma, fostering strategies that allow individuals to receive appropriate treatment for their mental disorders and physical health conditions, and promoting problem-focused coping styles.
- 1 November 2026
- Published by University of Toronto Press Inc. (UTPress) in Journal of Military, Veteran and Family Health
- Vol. 12 (5) , 131-142
Predictors of remission and progression of suicidal ideation in the Canadian Armed Forces: A 16-year nationally representative longitudinal study
Introduction: Given that suicidal ideation (SI) is a key risk factor for future suicidal behaviour, socio-economic and psychosocial factors that influence the critical transition period between suicidal ideation, plans, and attempts in the military should be examined. This study assessed correlates of remission and progression (i.e., worsening) of suicidality in a 16-year prospective, nationally representative sample of Canadian Armed Forces members and Veterans. Methods: The 2018 Canadian Armed Forces Members and Veterans Mental Health Follow-up Survey (n = 2,941) is a follow-up of respondents of the 2002 Canadian Community Health Survey – Canadian Forces Supplement. The reporting of SI in 2002 was used to create three groups in 2018: 1) remission (no SI, suicidal plans [SP], or suicidal attempts [SA] “since last interview”), 2) persistence (SI “since last interview”, but not SP or SA), and 3) progression (SP and/or SA “since last interview”). Results: Relative to SI persistence, all six mental disorders examined in 2018 were negatively associated with SI remission (odds ratio [OR] range 0.29-0.42) or positively associated with SI progression (OR range 3.69-5.92). Coping styles and deployment had statistically significant associations with remission, while military environmental command, military rank, physical health conditions, and traumatic exposure were significantly associated with progression. Discussion: Potential interventions could focus on developing psychological strategies to enhance resilience to trauma, fostering strategies that allow individuals to receive appropriate treatment for their mental disorders and physical health conditions, and promoting problem-focused coping styles.
- 14 February 2026
- Published by University of Toronto Press Inc. (UTPress) in Journal of Military, Veteran and Family Health
- Vol. 12 (4) , 20-32
Sex differences in early release from the military: Results from a 16-year follow-up study in Canada
Introduction: Despite the increasing participation of women in the military, there has been limited exploration of sex- and gender-specific considerations in early release scenarios. This study aims to understand the sex-specific factors associated with early release from the Canadian Armed Forces (CAF) and understand the prevalence, risk correlates, and protective factors involved using a nationally representative, 16-year follow-up survey of active duty CAF members. Methods: The 2018 CAF Members and Veterans Mental Health Follow-up Survey was a 16-year follow-up of 2,941 CAF Regular Force members who participated in the 2002 Canadian Community Health Survey-Canadian Forces Supplement (CCHS-CFS). The prevalence of males and females who were released following <10 and <20 years of service was calculated. Logistic regression analyses examined baseline (2002) and interim (2002-2018) risk and protective factors of releasing with <20 years of service. Results: Early release estimates were comparable between males (11.1%) and females (13.7%). Being non-white, serving in land and sea environments, having a higher number of dependents, having greater work stress at baseline, and avoidance coping positively predicted premature release in both sexes (OR 1.10-4.04). Younger age and a higher level of deployment-related experiences were associated with a lower likelihood of early release in both sexes (AOR 0.49-0.92). Surprisingly, trauma exposure and mental disorders were mostly not positively associated with early release. Discussion: Findings have implications for increasing military retention in both sexes. These implications include continued efforts to reduce work stress and unhelpful coping.
- 14 February 2026
- Published by University of Toronto Press Inc. (UTPress) in Journal of Military, Veteran and Family Health
- Vol. 12 (4) , 20-32
Sex differences in early release from the military: Results from a 16-year follow-up study in Canada
Introduction: Despite the increasing participation of women in the military, there has been limited exploration of sex- and gender-specific considerations in early release scenarios. This study aims to understand the sex-specific factors associated with early release from the Canadian Armed Forces (CAF) and understand the prevalence, risk correlates, and protective factors involved using a nationally representative, 16-year follow-up survey of active duty CAF members. Methods: The 2018 CAF Members and Veterans Mental Health Follow-up Survey was a 16-year follow-up of 2,941 CAF Regular Force members who participated in the 2002 Canadian Community Health Survey-Canadian Forces Supplement (CCHS-CFS). The prevalence of males and females who were released following <10 and <20 years of service was calculated. Logistic regression analyses examined baseline (2002) and interim (2002-2018) risk and protective factors of releasing with <20 years of service. Results: Early release estimates were comparable between males (11.1%) and females (13.7%). Being non-white, serving in land and sea environments, having a higher number of dependents, having greater work stress at baseline, and avoidance coping positively predicted premature release in both sexes (OR 1.10-4.04). Younger age and a higher level of deployment-related experiences were associated with a lower likelihood of early release in both sexes (AOR 0.49-0.92). Surprisingly, trauma exposure and mental disorders were mostly not positively associated with early release. Discussion: Findings have implications for increasing military retention in both sexes. These implications include continued efforts to reduce work stress and unhelpful coping.
- 1 February 2026
- Published by University of Toronto Press Inc. (UTPress) in Journal of Military, Veteran and Family Health
- Vol. 12 (1) , 17-33
Toward a definition of treatment-resistant posttraumatic stress disorder: A systematic review
Introduction: Posttraumatic stress disorder (PTSD) is a complex disorder that often persists despite the use of evidence-based treatments. This systematic review aims to synthesize existing definitions of treatment-resistant PTSD (TR-PTSD) and examine the criteria used across studies to inform future research and clinical guidelines. Methods: A systematic search was conducted in four databases. Studies were included if they reported on adult participants with TR-PTSD, regardless of definition, or described non-response to one or more treatments. A narrative synthesis was used to categorize findings and suggest refinements to a working TR-PTSD definition. Results: Of 4,046 screened articles, 55 studies met the inclusion criteria. We found substantial variation in how TR-PTSD was defined across studies. Studies investigated pharmacological (n = 19), psychosocial (n = 16), psychedelic-assisted (n = 7), and emerging treatments (n = 13). Findings highlighted diverse intervention strategies. Some reduced PTSD symptoms significantly, and others showed mixed or limited efficacy. Discussion: This study consolidates existing research on TR-PTSD, revealing significant variability in its definitions across studies. The lack of standardized criteria underscores the need for a more consistent framework to guide research and clinical decision-making. The authors propose a dynamic reassessment of treatment resistance that considers adherence, treatment delivery, comorbidities, and mechanisms of action. Future research should incorporate a broader range of treatment response indicators, such as biomarkers and clinical subtypes, to establish a standardized model for TR-PTSD. A clearer definition will improve patient care, aid in therapy selection, and support the development of more effective treatments.
- 1 February 2026
- Published by University of Toronto Press Inc. (UTPress) in Journal of Military, Veteran and Family Health
- Vol. 12 (1) , 17-33
Toward a definition of treatment-resistant posttraumatic stress disorder: A systematic review
Introduction: Posttraumatic stress disorder (PTSD) is a complex disorder that often persists despite the use of evidence-based treatments. This systematic review aims to synthesize existing definitions of treatment-resistant PTSD (TR-PTSD) and examine the criteria used across studies to inform future research and clinical guidelines. Methods: A systematic search was conducted in four databases. Studies were included if they reported on adult participants with TR-PTSD, regardless of definition, or described non-response to one or more treatments. A narrative synthesis was used to categorize findings and suggest refinements to a working TR-PTSD definition. Results: Of 4,046 screened articles, 55 studies met the inclusion criteria. We found substantial variation in how TR-PTSD was defined across studies. Studies investigated pharmacological (n = 19), psychosocial (n = 16), psychedelic-assisted (n = 7), and emerging treatments (n = 13). Findings highlighted diverse intervention strategies. Some reduced PTSD symptoms significantly, and others showed mixed or limited efficacy. Discussion: This study consolidates existing research on TR-PTSD, revealing significant variability in its definitions across studies. The lack of standardized criteria underscores the need for a more consistent framework to guide research and clinical decision-making. The authors propose a dynamic reassessment of treatment resistance that considers adherence, treatment delivery, comorbidities, and mechanisms of action. Future research should incorporate a broader range of treatment response indicators, such as biomarkers and clinical subtypes, to establish a standardized model for TR-PTSD. A clearer definition will improve patient care, aid in therapy selection, and support the development of more effective treatments.
- Open Access
- 19 January 2026
- Published by Springer Nature in Journal of Cannabis Research
- Vol. 8 (1)
Cannabis use among Canadian veterans: associations with the use of other substances, chronic pain conditions, mental disorders, suicide behaviours, and help-seeking
Background: A substantial proportion of Veterans experience mental and physical health difficulties, including post-traumatic stress disorder and chronic pain, for which cannabis is sometimes medically authorized. However, relatively little is known about cannabis use among Canadian Veterans. Information on the prevalence of use, as well as the mental health profiles and help-seeking behaviours of Veterans who use cannabis, is important for developing more targeted prevention and intervention services and supports. Methods: The current study used data from Veteran respondents ( n = 1992) of the 2018 Canadian Armed Forces Members and Veterans Mental Health Follow-up Survey. Descriptive statistics and logistic regression models were used to examine associations between past 12-month cannabis use and concurrent mental disorders, chronic pain conditions, use of other substances, suicide behaviours, perceived need for care, and help-seeking behaviours. Results: Several participating Veterans (16.7%) reported using cannabis in the past 12-months. Infrequent use of cannabis in the past 12 months was associated with statistically significantly increased odds of current smoking, binge drinking, and post-traumatic stress disorder in fully adjusted models (Adjusted odds ratios [AOR-2] = 1.93, 2.58, and 2.37, respectively). Regular use of cannabis in the past 12 months was associated with statistically significantly increased odds of current tobacco smoking, arthritis and any chronic pain condition, several mental health disorders, and suicide ideation in fully adjusted models (AOR-2 ranged from 1.61 to 3.99). Veterans who used cannabis both infrequently and regularly were also statistically significantly more likely to perceive a need for care (AOR-2 = 2.15 and 4.85, respectively) and report professional help-seeking (AOR-2 = 2.25 and 5.56, respectively) in the past 12-months compared to Veterans who did not use cannabis. Conclusions: The strong association of past 12-month cannabis use with nicotine, chronic pain, mental disorders, and suicide ideation suggests that Veterans who use cannabis regularly may represent a population with complex needs who may benefit from additional services and supports. Cannabis using Veterans were also more likely to perceive a need for and seek professional help, which provides opportunities for more timely identification and intervention.
- 19 January 2026
- Published by Springer Nature in Journal of Cannabis Research
- Vol. 8 (1)
Open AccessCannabis use among Canadian veterans: associations with the use of other substances, chronic pain conditions, mental disorders, suicide behaviours, and help-seeking
Background: A substantial proportion of Veterans experience mental and physical health difficulties, including post-traumatic stress disorder and chronic pain, for which cannabis is sometimes medically authorized. However, relatively little is known about cannabis use among Canadian Veterans. Information on the prevalence of use, as well as the mental health profiles and help-seeking behaviours of Veterans who use cannabis, is important for developing more targeted prevention and intervention services and supports. Methods: The current study used data from Veteran respondents ( n = 1992) of the 2018 Canadian Armed Forces Members and Veterans Mental Health Follow-up Survey. Descriptive statistics and logistic regression models were used to examine associations between past 12-month cannabis use and concurrent mental disorders, chronic pain conditions, use of other substances, suicide behaviours, perceived need for care, and help-seeking behaviours. Results: Several participating Veterans (16.7%) reported using cannabis in the past 12-months. Infrequent use of cannabis in the past 12 months was associated with statistically significantly increased odds of current smoking, binge drinking, and post-traumatic stress disorder in fully adjusted models (Adjusted odds ratios [AOR-2] = 1.93, 2.58, and 2.37, respectively). Regular use of cannabis in the past 12 months was associated with statistically significantly increased odds of current tobacco smoking, arthritis and any chronic pain condition, several mental health disorders, and suicide ideation in fully adjusted models (AOR-2 ranged from 1.61 to 3.99). Veterans who used cannabis both infrequently and regularly were also statistically significantly more likely to perceive a need for care (AOR-2 = 2.15 and 4.85, respectively) and report professional help-seeking (AOR-2 = 2.25 and 5.56, respectively) in the past 12-months compared to Veterans who did not use cannabis. Conclusions: The strong association of past 12-month cannabis use with nicotine, chronic pain, mental disorders, and suicide ideation suggests that Veterans who use cannabis regularly may represent a population with complex needs who may benefit from additional services and supports. Cannabis using Veterans were also more likely to perceive a need for and seek professional help, which provides opportunities for more timely identification and intervention.
- Open Access
- 13 December 2025
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 61 (8) , 1137-1145
Problematic Prescription Drug Use Among Canadian Armed Forces Veterans: Data from the Canadian Armed Forces Members and Veterans Mental Health Follow-Up Survey (CAFVMHS)
Problematic prescription drug use (PPDU) is a public health concern that can cause degradation of wellbeing. Examination of prevalence and correlates of PPDU in Canadian Armed Forces (CAF) Veterans is essential to understand its impact and to identify those at risk. This study aimed to assess correlates of PPDU among CAF Veterans, including sociodemographic characteristics and physical and mental disorders. Data were drawn from the 2018 CAF Members and Veterans Mental Health Follow-up Survey (n = 1,922), all of whom indicated Veteran status at the time of the survey. PPDU was defined as utilization of a prescription drug without a prescription, in excess to the amount prescribed, for recreational purposes, or to a level where the individual felt they could not stop usage. PPDU included three categories of substances: sedatives/tranquilizers, stimulants, and analgesics. Nine percent of Veterans indicated PPDU in the past year, while 16.8% endorsed PPDU in their lifetime. Being unpartnered increased the odds of PPDU, while older age, air environment, and officer rank were associated with lower odds. Past-year presence of a mental disorder, alcohol use disorder, suicidal behavior, chronic pain condition, and greater number of physical health conditions demonstrated positive associations with PPDU (Adjusted Odds Ratios [AORs] ranging from 1.36 to 5.31). Increasing number of traumatic events and deployment-related experiences led to greater odds of PPDU (AORs of 1.12 and 1.16, respectively). Results highlight the vulnerability of the CAF Veteran population to PPDU. Correlates noted may aid in the development of supports to promote the mental health of Veterans.
- 13 December 2025
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 61 (8) , 1137-1145
Open AccessProblematic Prescription Drug Use Among Canadian Armed Forces Veterans: Data from the Canadian Armed Forces Members and Veterans Mental Health Follow-Up Survey (CAFVMHS)
Problematic prescription drug use (PPDU) is a public health concern that can cause degradation of wellbeing. Examination of prevalence and correlates of PPDU in Canadian Armed Forces (CAF) Veterans is essential to understand its impact and to identify those at risk. This study aimed to assess correlates of PPDU among CAF Veterans, including sociodemographic characteristics and physical and mental disorders. Data were drawn from the 2018 CAF Members and Veterans Mental Health Follow-up Survey (n = 1,922), all of whom indicated Veteran status at the time of the survey. PPDU was defined as utilization of a prescription drug without a prescription, in excess to the amount prescribed, for recreational purposes, or to a level where the individual felt they could not stop usage. PPDU included three categories of substances: sedatives/tranquilizers, stimulants, and analgesics. Nine percent of Veterans indicated PPDU in the past year, while 16.8% endorsed PPDU in their lifetime. Being unpartnered increased the odds of PPDU, while older age, air environment, and officer rank were associated with lower odds. Past-year presence of a mental disorder, alcohol use disorder, suicidal behavior, chronic pain condition, and greater number of physical health conditions demonstrated positive associations with PPDU (Adjusted Odds Ratios [AORs] ranging from 1.36 to 5.31). Increasing number of traumatic events and deployment-related experiences led to greater odds of PPDU (AORs of 1.12 and 1.16, respectively). Results highlight the vulnerability of the CAF Veteran population to PPDU. Correlates noted may aid in the development of supports to promote the mental health of Veterans.
- Open Access
- 14 August 2025
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 35 (3) , S57-S89
Interventional Psychiatry and Emerging Treatments for Posttraumatic Stress Disorder (PTSD): A Systematic Review
Posttraumatic stress disorder (PTSD) is a severe, often difficult-to-treat condition, highlighting the need for innovative therapies. Interventional treatments, including neuromodulation, rapid-acting pharmacotherapies such as intravenous ketamine (IV-KET) and esketamine (ESK), and emerging psychedelic-assisted psychotherapies, offer promising solutions. This systematic review evaluates the efficacy, safety, and future research priorities of these treatments for PTSD. A search strategy was implemented across 3 electronic databases. Peer-reviewed articles written in English that focused on interventional psychiatry treatments for adult patients with PTSD were included. The systematic review encompassed 94 studies, including 39 on transcranial magnetic stimulation (TMS), 8 on IV-KET, 3 on intranasal esketamine (IN-ESK), 4 on intravenous ketamine (IV-KET) assisted therapy (KET-AT), 1 on esketamine (ESK) assisted therapy (ESK-AT), and 14 on 3,4-methylenedioxymethamphetamine assisted therapy (MDMA-AT). Randomized controlled trials demonstrated response rates of 12.5%-80% for TMS, 17%-67% for IV-KET, and 50%-87% for MDMA. Additional treatments reviewed included Electroconvulsive Therapy, transcranial direct current stimulation, and other pharmacological and neurostimulation treatments. Most treatments were well tolerated, with only mild, transient adverse effects. This review highlights the heterogeneity in efficacy, safety, and tolerability across neuromodulation and pharmacologic treatments for PTSD. Variability in response rates reflects differences in patient populations, protocols, and comorbidities. While repetitive TMS, IV-KET, ESK, KET-AT, and MDMA-AT show symptom improvement, sustained efficacy varies, underscoring the need for maintenance strategies. Although direct evidence on stage-specific approaches is limited, these methods, guided by neuroscience-based nomenclature, may improve therapeutic precision, especially in complex cases.
- 14 August 2025
- Published by AVES YAYINCILIK A.Ş. in Psychiatry and Clinical Psychopharmacology
- Vol. 35 (3) , S57-S89
Open AccessInterventional Psychiatry and Emerging Treatments for Posttraumatic Stress Disorder (PTSD): A Systematic Review
Posttraumatic stress disorder (PTSD) is a severe, often difficult-to-treat condition, highlighting the need for innovative therapies. Interventional treatments, including neuromodulation, rapid-acting pharmacotherapies such as intravenous ketamine (IV-KET) and esketamine (ESK), and emerging psychedelic-assisted psychotherapies, offer promising solutions. This systematic review evaluates the efficacy, safety, and future research priorities of these treatments for PTSD. A search strategy was implemented across 3 electronic databases. Peer-reviewed articles written in English that focused on interventional psychiatry treatments for adult patients with PTSD were included. The systematic review encompassed 94 studies, including 39 on transcranial magnetic stimulation (TMS), 8 on IV-KET, 3 on intranasal esketamine (IN-ESK), 4 on intravenous ketamine (IV-KET) assisted therapy (KET-AT), 1 on esketamine (ESK) assisted therapy (ESK-AT), and 14 on 3,4-methylenedioxymethamphetamine assisted therapy (MDMA-AT). Randomized controlled trials demonstrated response rates of 12.5%-80% for TMS, 17%-67% for IV-KET, and 50%-87% for MDMA. Additional treatments reviewed included Electroconvulsive Therapy, transcranial direct current stimulation, and other pharmacological and neurostimulation treatments. Most treatments were well tolerated, with only mild, transient adverse effects. This review highlights the heterogeneity in efficacy, safety, and tolerability across neuromodulation and pharmacologic treatments for PTSD. Variability in response rates reflects differences in patient populations, protocols, and comorbidities. While repetitive TMS, IV-KET, ESK, KET-AT, and MDMA-AT show symptom improvement, sustained efficacy varies, underscoring the need for maintenance strategies. Although direct evidence on stage-specific approaches is limited, these methods, guided by neuroscience-based nomenclature, may improve therapeutic precision, especially in complex cases.
- Open Access
- 12 June 2025
- Published by Springer Nature in Canadian Journal of Public Health
- Vol. 117 (1) , 62-73
Disorder-specific risk factors of suicidal behaviour among serving and veteran Canadian Armed Forces Members with baseline mental health diagnoses
Objectives: Many Canadian Armed Forces (CAF) members and veterans will receive a mental disorder diagnosis, and a high percentage will also experience suicidal behaviours. This study examined demographic characteristics, distal and proximal risk factors, and protective factors, and their relationship to suicidal behaviour (ideation, plans, and attempts) among CAF members and veterans who met criteria for a mental disorder at baseline. Methods: Data from the 2018 CAF Members and Veterans Mental Health Follow-up Survey ( n = 2941) were utilized. Mental disorder diagnoses were assessed through structured diagnostic interview. Generalized linear models were conducted using subsamples of individuals with a lifetime baseline diagnosis of (a) major depressive episode (MDE), (b) posttraumatic stress disorder (PTSD), and (c) an anxiety disorder (AD; social phobia, generalized, panic). Results: Across mental disorder subsamples of those with MDE and AD, land environmental command at baseline was associated with increased prevalence of suicidal behaviour. Risk factors for suicidal behaviour across all subsamples included baseline suicidal behaviour, greater level of self-medication and avoidant coping style, greater level of baseline work stress, greater number of traumatic experiences, persistence or recurrence of index mental disorder, current comorbid mental disorder, current physical health condition, exposure to “other” traumatic experiences, and alcohol use disorder. Protective factors across all subsamples included greater level of current problem-solving coping style. Disorder-specific factors were also identified. Conclusion: This study identified characteristics of individuals living with mental disorders who might be at high risk of suicidal behaviour, highlighting potential areas for targeted interventions in this key population.
- 12 June 2025
- Published by Springer Nature in Canadian Journal of Public Health
- Vol. 117 (1) , 62-73
Open AccessDisorder-specific risk factors of suicidal behaviour among serving and veteran Canadian Armed Forces Members with baseline mental health diagnoses
Objectives: Many Canadian Armed Forces (CAF) members and veterans will receive a mental disorder diagnosis, and a high percentage will also experience suicidal behaviours. This study examined demographic characteristics, distal and proximal risk factors, and protective factors, and their relationship to suicidal behaviour (ideation, plans, and attempts) among CAF members and veterans who met criteria for a mental disorder at baseline. Methods: Data from the 2018 CAF Members and Veterans Mental Health Follow-up Survey ( n = 2941) were utilized. Mental disorder diagnoses were assessed through structured diagnostic interview. Generalized linear models were conducted using subsamples of individuals with a lifetime baseline diagnosis of (a) major depressive episode (MDE), (b) posttraumatic stress disorder (PTSD), and (c) an anxiety disorder (AD; social phobia, generalized, panic). Results: Across mental disorder subsamples of those with MDE and AD, land environmental command at baseline was associated with increased prevalence of suicidal behaviour. Risk factors for suicidal behaviour across all subsamples included baseline suicidal behaviour, greater level of self-medication and avoidant coping style, greater level of baseline work stress, greater number of traumatic experiences, persistence or recurrence of index mental disorder, current comorbid mental disorder, current physical health condition, exposure to “other” traumatic experiences, and alcohol use disorder. Protective factors across all subsamples included greater level of current problem-solving coping style. Disorder-specific factors were also identified. Conclusion: This study identified characteristics of individuals living with mental disorders who might be at high risk of suicidal behaviour, highlighting potential areas for targeted interventions in this key population.
- Open Access
- 28 July 2024
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 262, 111408
Coping style as a risk factor for future alcohol use disorder: A 16-year longitudinal study in a Canadian military sample
- 28 July 2024
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 262, 111408
Open AccessCoping style as a risk factor for future alcohol use disorder: A 16-year longitudinal study in a Canadian military sample
- Open Access
- 16 July 2024
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 18 (6) , 683-688
Trend in Prescription Medication Utilization for Opioid Use Disorder and Alcohol Use Disorder From 2015 to 2021: A Population-wide Study in a Canadian Province
Objective: To examine the quarterly incidence and prevalence of medications for opioid use disorder (OUD) and alcohol use disorder (AUD) from 2015 to 2021. Methods: A retrospective population-wide observational study in Manitoba, Canada, was conducted using administrative claims data from the Manitoba Centre for Health Policy to examine the incidence and prevalence of OUD (methadone, buprenorphine-naloxone, buprenorphine) or AUD medications (naltrexone, acamprosate, disulfiram) per 10,000 individuals in each quarter between January 1, 2015, and December 31, 2021. Results: There were 1179 and 451 individuals who received at least one prescription for OUD and AUD, respectively, in the first quarter of 2020. The prevalence of OUD medications more than doubled from 6.3 to 14.3 per 10,000 from January 1, 2015, to December 31, 2021. Likewise, AUD medication prevalence increased almost 10-fold from 0.68 to 6.5 per 10,000 from January 1, 2015, to December 31, 2021, primarily due to naltrexone. The incidence of AUD prescription use increased 8.6-fold from 0.29 to 2.51 per 10,000 during the study period. In contrast, the incidence of opioid agonist therapy declined from 2.1 per 10,000 in the first quarter of 2015 to 0.53 per 10,000 the first quarter of 2016, primarily due to methadone. Whereas methadone incidence declined, buprenorphine-naloxone incidence increased almost 15-fold during the study period. Conclusion: An increase in both AUD medication prevalence and incidence in addition to an increase in buprenorphine-naloxone incidence was observed. These findings reflect an increase in the uptake of medications for treating AUD and OUD following changes to improve coverage and access to these medications.
- 16 July 2024
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 18 (6) , 683-688
Open AccessTrend in Prescription Medication Utilization for Opioid Use Disorder and Alcohol Use Disorder From 2015 to 2021: A Population-wide Study in a Canadian Province
Objective: To examine the quarterly incidence and prevalence of medications for opioid use disorder (OUD) and alcohol use disorder (AUD) from 2015 to 2021. Methods: A retrospective population-wide observational study in Manitoba, Canada, was conducted using administrative claims data from the Manitoba Centre for Health Policy to examine the incidence and prevalence of OUD (methadone, buprenorphine-naloxone, buprenorphine) or AUD medications (naltrexone, acamprosate, disulfiram) per 10,000 individuals in each quarter between January 1, 2015, and December 31, 2021. Results: There were 1179 and 451 individuals who received at least one prescription for OUD and AUD, respectively, in the first quarter of 2020. The prevalence of OUD medications more than doubled from 6.3 to 14.3 per 10,000 from January 1, 2015, to December 31, 2021. Likewise, AUD medication prevalence increased almost 10-fold from 0.68 to 6.5 per 10,000 from January 1, 2015, to December 31, 2021, primarily due to naltrexone. The incidence of AUD prescription use increased 8.6-fold from 0.29 to 2.51 per 10,000 during the study period. In contrast, the incidence of opioid agonist therapy declined from 2.1 per 10,000 in the first quarter of 2015 to 0.53 per 10,000 the first quarter of 2016, primarily due to methadone. Whereas methadone incidence declined, buprenorphine-naloxone incidence increased almost 15-fold during the study period. Conclusion: An increase in both AUD medication prevalence and incidence in addition to an increase in buprenorphine-naloxone incidence was observed. These findings reflect an increase in the uptake of medications for treating AUD and OUD following changes to improve coverage and access to these medications.
- Open Access
- 21 August 2023
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 174, 111473
A longitudinal study of distress symptoms and work impairment in immune-mediated inflammatory diseases
- 21 August 2023
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 174, 111473
Open AccessA longitudinal study of distress symptoms and work impairment in immune-mediated inflammatory diseases